{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:04:37Z","timestamp":1793084677138,"version":"4.5.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Single antigen\u2013targeted chimeric antigen receptor (CAR) T-cell therapy may be insufficient to induce a durable response in pediatric aggressive B-cell lymphomas. This clinical trial examined the feasibility of sequential different B-cell antigen\u2013targeted CAR T-cell therapy for pediatric relapsed\/refractory (R\/R) Burkitt lymphoma. Twenty-three patients received the first CD19 CAR T-cell infusion. The patients who did not achieve an ongoing complete response (CR) underwent 1 or more sequential infusions of CAR T-cell therapy that targeted CD22 followed by CD20 according to their disease status and CAR T-cell persistence after each infusion. The median time from the last infusion to the cutoff date was 17 months (range, 15-23 months). The estimated 18-month CR rate was 78% (95% confidence interval [CI], 54%-91%). The estimated 18-month progression-free survival rate was 78% (95% CI, 55%-90%), with 78% (95% CI, 37%-94%) in patients with bulky disease and 60% (95% CI, 25%-83%) in patients with central nervous system (CNS) involvement. During the first CD19 CAR T-cell infusion, grade \u22653 cytokine release syndrome (CRS) occurred in 34.8% and neurotoxicity occurred in 21.7% of all patients. During subsequent infusions, there were only a few incidences of grade &amp;gt;2 CRS and neurotoxicity. All adverse events were reversible. The severity of neurotoxicity was not significantly different between patients with CNS involvement and those who did not have CNS involvement. Sequential CAR T-cell therapy may result in a durable response and is safe in pediatric R\/R Burkitt lymphoma. Patients with CNS involvement may benefit from sequential CAR T-cell therapy. This trial was registered at www.chictr.org.cn\/index.aspx as #ChiCTR1800014457.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004557","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T21:59:54Z","timestamp":1631656794000},"page":"717-730","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Sequential different B-cell antigen\u2013targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma"],"prefix":"10.1182","volume":"6","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[{"name":"Cytology Laboratory, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Medical Laboratory, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Yu","sequence":"additional","affiliation":[{"name":"Medical Laboratory, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifen","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking University Third Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunju","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Center for Children\u2019s Health, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences\/School of Basic Medicine, Peking Union Medical College, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Center for Children\u2019s Health, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Center for Children\u2019s Health, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Boren Hospital, Beijing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[{"name":"Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Lymphoma,"},{"name":"Department of Hematology\/Oncology, National Center for Children\u2019s Health, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"11","key":"2022012716231232000_B1","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood."},{"issue":"3","key":"2022012716231232000_B2","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood."},{"issue":"7","key":"2022012716231232000_B3","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood."},{"issue":"7","key":"2022012716231232000_B4","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood."},{"issue":"6","key":"2022012716231232000_B5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin\u2019s lymphoma: results of the FAB\/LMB 96 international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br J Haematol."},{"issue":"4","key":"2022012716231232000_B6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u2265 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB LMB 96 study","volume":"30","author":"Cairo","year":"2012","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022012716231232000_B7","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia."},{"issue":"2","key":"2022012716231232000_B8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15520","article-title":"Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB\/LMB96 and COG ANHL01P1","volume":"185","author":"Frazer","year":"2019","journal-title":"Br J Haematol."},{"issue":"23","key":"2022012716231232000_B9","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med."},{"issue":"2","key":"2022012716231232000_B10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/pbc.21585","article-title":"The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan","volume":"51","author":"Fujita","year":"2008","journal-title":"Pediatr Blood Cancer."},{"issue":"10","key":"2022012716231232000_B11","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3109\/10428194.2012.677534","article-title":"Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia","volume":"53","author":"Anoop","year":"2012","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"2022012716231232000_B12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2014.121434","article-title":"Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \u201cLymphomes Malins B\u201d protocols. A Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers de l\u2019Enfant study","volume":"100","author":"Jourdain","year":"2015","journal-title":"Haematologica."},{"issue":"6","key":"2022012716231232000_B13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.15491","article-title":"Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB\/LMB 96: a report from the FAB\/LMB 96 study group","volume":"182","author":"Cairo","year":"2018","journal-title":"Br J Haematol."},{"issue":"14","key":"2022012716231232000_B14","first-page":"1124","article-title":"Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy","volume":"135","author":"Woessmann","year":"2020","journal-title":"Blood."},{"issue":"8","key":"2022012716231232000_B15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.6004\/jnccn.2020.7608","article-title":"Novel therapies potentially available for pediatric B-cell non-Hodgkin lymphoma","volume":"18","author":"Harker-Murray","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"2022012716231232000_B16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/hematology.2020000133","article-title":"Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma","volume":"2020","author":"Hsieh","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"26","key":"2022012716231232000_B17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"26","key":"2022012716231232000_B18","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2022012716231232000_B19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2022012716231232000_B20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10254","key":"2022012716231232000_B21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"key":"2022012716231232000_B22","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol."},{"issue":"12","key":"2022012716231232000_B23","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"issue":"7750","key":"2022012716231232000_B24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature."},{"issue":"1","key":"2022012716231232000_B25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-020-00197-1","article-title":"Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies","volume":"8","author":"Nie","year":"2020","journal-title":"Biomark Res."},{"key":"2022012716231232000_B26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics."},{"issue":"14","key":"2022012716231232000_B27","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood."},{"key":"2022012716231232000_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from Zuma-6: axicabtagene ciloleucel (axi-cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma [abstract]","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood."},{"issue":"5","key":"2022012716231232000_B29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood."},{"issue":"26","key":"2022012716231232000_B30","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.2019002008","article-title":"Early response observed in pediatric patients with relapsed\/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells","volume":"135","author":"Zhang","year":"2020","journal-title":"Blood."},{"issue":"20","key":"2022012716231232000_B31","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood-2016-03-657379","article-title":"Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood."},{"issue":"12","key":"2022012716231232000_B32","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia."},{"issue":"12","key":"2022012716231232000_B33","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia."},{"issue":"18","key":"2022012716231232000_B34","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised international pediatric non-Hodgkin lymphoma staging system","volume":"33","author":"Rosolen","year":"2015","journal-title":"J Clin Oncol."},{"issue":"18","key":"2022012716231232000_B35","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.2014.59.0745","article-title":"International pediatric non-Hodgkin lymphoma response criteria","volume":"33","author":"Sandlund","year":"2015","journal-title":"J Clin Oncol."},{"issue":"16","key":"2022012716231232000_B36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"issue":"2","key":"2022012716231232000_B37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica."},{"issue":"5","key":"2022012716231232000_B38","first-page":"375","article-title":"The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma","volume":"16","author":"Lulla","year":"2018","journal-title":"Clin Adv Hematol Oncol."},{"issue":"4","key":"2022012716231232000_B39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"23","key":"2022012716231232000_B40","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood."},{"key":"2022012716231232000_B41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The pharmacology of T cell therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"5","key":"2022012716231232000_B42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the tumor microenvironment in mature B-cell lymphoid malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica."},{"issue":"8","key":"2022012716231232000_B43","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy","volume":"103","author":"de Charette","year":"2018","journal-title":"Haematologica."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/717\/1864925\/advancesadv2021004557.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/717\/1864925\/advancesadv2021004557.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T16:23:56Z","timestamp":1643300636000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/3\/717\/476898\/Sequential-different-B-cell-antigen-targeted-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004557","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}